Crown Bioscience: First Clinical Candidate Developed Using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428006002/en/
The study was the result of work by an international consortium, SuppresSTEM which included Crown Bioscience (previously OcellO B.V.) and HUB. Crown Bioscience and HUB led the design of the experiments which were executed using the high content screening platform from Crown Bioscience using HUB Organoids. These studies enabled the discrimination of antibodies that were active against a broad range of mutational profiles and tumor subtypes, with hit validation and mechanism of action studies that enabled selection of optimally performing antibodies. Follow up in vivo studies in matched patient-derived xenograft (PDX) models were also performed by Crown Bioscience.
The work, spanning about five years, involved Crown Bioscience screening a library of hundreds of bispecific antibodies and rescreening of ‘hits’ in a panel of patient-derived colorectal cancer organoids and matching normal organoids, that were developed by HUB and characterized by HUB and other consortium members. Organoids are stem cell-derived mini-organs developed from any patient resection or biopsy tissue that can be grown in the laboratory, which can be applied like conventional cell lines in early drug discovery.
“This is the first study that has used organoids exclusively for cell-based compound screening and characterization, leading to a compound entering clinical trials. This is a truly remarkable achievement that demonstrates the validity and application of HUB Organoids in high throughput screening and oncology drug discovery”, said Leo Price PhD, Senior Vice President In Vitro Oncology at Crown Bioscience.
“This groundbreaking work demonstrates the power and potential of HUB Organoid Technology”, commented Rob Vries PhD, CEO at HUB. “Using organoids, we were able to accelerate the timeline from initial discovery to clinical trials to about five years.”
Nature Cancer is a journal which covers the latest, most significant cancer-related advances across the life, physical, applied and social sciences, focusing on new approaches for the development and delivery of diagnostics and therapeutics, as well as clinical studies regarding cancer diagnosis, treatment and prevention.
Read the full paper here: https://go.nature.com/3LhuAAy
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. The company is the only preclinical CRO to hold a commercial license to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe and Asia. Find out more: https://www.crownbio.com.
About HUB
HUB Organoids (HUB) is the global leader in the field of adult stem cell-derived organoid. The technology invented by HUB’s scientists in the lab of world-renowned Prof. Hans Clevers represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics. HUB offers licenses to its proprietary technology and provides drug screening services and access to its living organoid biobanks.
About SupresStem
The SuppresSTEM consortium was funded by EU FP7 and involved collaborative work by companies including OcellO B.V./Crown Bioscience, HUB Organoids, and Merus N.V., and international research institutions including the Hubrecht Institute, IRB Barcelona and the Sanger Institute. The Vall d'Hebron Institute of Oncology (VHIO), the Catalan Institute of Oncology and the company Xenopad also collaborated in data for this publication. The consortium set out to develop novel antibody-based therapeutics targeting cancer stem cells for the treatment of colorectal cancer as well as patient-derived organoid-based screening tools to aid drug discovery.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428006002/en/
Contact information
Media Enquiries
Crown Bioscience
Louise Stenson
pr@crownbio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Frontgrade Unveils RT-SADE: Precision Motor Control for Next-Gen Space Missions19.11.2025 14:00:00 EET | Press release
Frontgrade™ Technologies, a leading provider of high-reliability electronic solutions for space and national security missions, today announced the release of the RT-SADE (Radiation-Tolerant Solar Array Drive Electronics), a next-generation microprocessor-based stepper motor controller engineered to deliver precision, reliability, and versatility for demanding spacecraft and defense applications. Designed for mission-critical motion control systems such as solar array drives, RT-SADE combines radiation-tolerant electronics, advanced fault management, and flexible configuration options to give customers superior performance and confidence in the harshest environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119546361/en/ Built around a microprocessor and advanced circuitry rated to 30 krad total ionizing dose, RT-SADE ensures long-term durability and mission assurance for Low- to Medium-Earth Orbit (LEO/MEO) operati
Murata Named Top Innovator for UltraSonic Clearing Device Technology Advancing All-Weather ADAS19.11.2025 14:00:00 EET | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has been selected as a Top Innovator in the Digital category of the CLEPA Innovation Awards. The award recognizes Murata’s UltraSonic Clearing Device (USCD) technology, which is currently in development to augment the effectiveness of cameras and sensors used in advanced driver assistance systems (ADAS) and autonomous driving applications, regardless of weather conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251119372516/en/ [Murata Manufacturing Co., Ltd.] CLEPA While current camera and sensor technologies often rely on ideal operating conditions, their performance can be negatively impacted by rain, fog, dust, ice, and snow. Murata’s USCD technology is addressing this challenge by using ultrasonic vibrations to disperse water and remove debris from the camera lens and sensor, maintaining visibility. The ultrasonic vibrations also heat the outer le
CMOs Face a ‘Reputation and Results’ Reckoning, According to NIQ’s 2026 Outlook19.11.2025 13:00:00 EET | Press release
NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released its CMO Outlook: Guide to 2026 report, revealing how chief marketing officers (CMOs) are navigating a critical inflection point between brand building and revenue accountability. According to the report, 83% of CMOs remain confident in their brand’s equity, even as they face tightening budgets and heightened scrutiny over ROI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118947080/en/ NIQ CMO Outlook: Guide to 2026 “Every marketing dollar is now under the microscope,” said Marta Cyhan-Bowles, Chief Communications Officer & Head of Global Marketing COE, NIQ. “With organizations prioritizing cost reductions, CMOs are being challenged not just to spend wisely, but to prove how marketing directly drives awareness, growth, and loyalty. It’s no longer just about efficiency; it’s about proving impact – all with largely flat budgets.” Key Findings f
Data Space Technology Leaders Advance Data Interoperability in Construction and Real Estate at the Gaia-X Summit19.11.2025 12:03:00 EET | Press release
Leaders in data space technology are converging at the Gaia-X Summit, in Porto November 20-21, to address the imperative of interoperability within and across data spaces in the construction and real estate sectors. The main objective is to assess how data spaces can leverage the world’s estimated $393 trillion in real estate assets. Achieving this involves exploring numerous use cases among the entire building lifecycle, from design to demolition, including construction, renovation and facility management operations, which creates a win-win situation for both industry and technology stakeholders. In France, the construction and renovation market alone is estimated at €200 billion annually. Designed to address the sector’s challenges, Digital TER-X is a technology demonstrator serving the construction and real estate use cases. Its relevance has been recognized, notably by being named in November 2025 Gaia-X Lighthouse Project, just one year after its Gaia-X Endorsed Project status, an
Quectel Takes Smart Meters to the Next Generation at Enlit 202519.11.2025 11:00:00 EET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, has announced it is attending the Enlit 2025 event in Bilbao, Spain on 18-20 November 2025 and will be at Stand 1.G86. Quectel is attending to showcase how its comprehensive range of modules, antennas and services are poised to assist continued massive uptake of smart meters and assist industry moves from first to second-generation devices. With deployments of smart meters, comprised of electricity, water and gas meters, exceeding 1.06 billion at the end of 2023 and set to continue in all regions, according to IoT Analytics, Quectel is seeing growth across all meter types and expansion of meter-based use cases. Smart electricity meters are being deployed in developing markets for the first time and mature markets are accelerating deployments of second-generation smart meters to help users optimize consumption and manage their own power generation via two-way metering communications. Growth is being experienced acr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom